Pep2Dia® is the result of extensive research and collaboration between Ingredia’s scientists and LIENSs-CNRS La Rochelle University in France. Pep2Dia® has proven efficacy on glycaemia after meals. Pre-clinical and clinical studies support Pep2Dia®’s action to reduce postprandial glycaemia with a significative effect versus the placebo.
Ingredia Launches PEP2DIA®: An Innovative Bioactive for Blood Sugar Management
